Immunomodulatory MSC Exosome and Small Extracellular Vesicles
Sai Kiang Lim,
Research Director,
A*STAR Institute of Medical Biology
Mesenchymal stromal cell (MSC) are the most clinically tested cell type for regenerative medicine. Despite much setbacks, MSC is now gaining traction as a safe. viable regenerative medicine with recent market approval for use in GVHD and Crohn’s disease. However, it is increasingly clear that small extracellular vesicles (sEVs) of 50 to 200 nm diameter such as exosomes mediate the therapeutic potency of MSCs. Since the first demonstration that MSC secretes cardioprotective sEVs in a mouse and pig models of myocardial ischemia/reperfusion injury, these sEVs were widely reported to therapeutically efficacious against at least 30 other indications. A common observation in many MSC sEV-mediated efficacies is a significant immunomodulatory effect. This talk will describe our studies on the immunomodulatory potential of MSC sEVs.
|
|
